<seo title="Dexcom" metakeywords="diabetes 2006 dexcom,glucose monitoring systems,dexcom medical device,glucose monitoring" metadescription="Dexcom is a medical device company that specializes in the development and commercialization of continuous glucose monitoring (CGM) systems." />
===Introduction to Dexcom===

Dexcom is a medical device company that specializes in the development and commercialization of continuous glucose monitoring (CGM) systems. The company was founded in 1999 and is headquartered in San Diego, California. Dexcom’s mission is to improve the lives of people with diabetes by providing innovative, easy-to-use, and accurate glucose monitoring systems. Dexcom’s products are designed to help people with diabetes better manage their condition and improve their quality of life.
===History of Dexcom===

Dexcom was founded in 1999 by two engineers, John Burd and George Burd. The company was initially focused on developing a continuous glucose monitoring system for people with diabetes. In 2006, Dexcom received FDA approval for its first CGM system, the Seven Plus. Since then, the company has continued to develop and improve its CGM systems, and in 2012, Dexcom received FDA approval for its G4 Platinum CGM system.
===Products and Services Offered by Dexcom===

Dexcom offers a range of products and services designed to help people with diabetes better manage their condition. The company’s flagship product is its G4 Platinum CGM system, which is designed to provide real-time glucose readings and alerts. Dexcom also offers a range of accessories, such as the Dexcom G6 transmitter and receiver, which allow users to monitor their glucose levels remotely. In addition, Dexcom offers a range of software and mobile apps, such as the Dexcom Follow app, which allows users to share their glucose data with family and friends.
===Financial Performance of Dexcom===

Dexcom has experienced strong [[Financial Performance|financial performance]] in recent years. In 2020, the company reported total revenue of $1.7 billion, a year-over-year increase of 28%. The company’s [[Net Income|net income]] also increased significantly, from $90 million in 2019 to $220 million in 2020. Dexcom’s strong financial performance is largely due to the increasing demand for its CGM systems, as well as the company’s focus on developing innovative products and services.
===Conclusion===

Dexcom is a medical device company that specializes in the development and commercialization of continuous glucose monitoring (CGM) systems. The company has experienced strong financial performance in recent years, due to the increasing demand for its products and services. Dexcom’s mission is to improve the lives of people with diabetes by providing innovative, easy-to-use, and accurate glucose monitoring systems